Abstract: Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having breast cancer. Also provided herein are methods and kits for determining the prognosis of a subject having breast cancer and for determining the progression of breast cancer in a subject.

Abstract: Disclosed herein are systems, methods, devices, and media for carrying out detection of ophthalmic and systemic diseases and disorders. Deep learning algorithms enable the automated analysis of ophthalmic images such as retinal scans to generate accurate detection of various diseases and disorders. Point-of-care implementations allow for rapid and efficient detection outside of the clinical setting.

Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).

Abstract: Disclosed herein are systems, methods, devices, and media for carrying out diagnosis of myopia onset and progression. Machine learning algorithms enable the automated analysis of relevant features to generate predictions. Also disclosed are treatment methods incorporating the machine learning algorithms to identify suitable treatments and predict treatment efficacy.

Abstract: Disclosed herein are methods and systems for Artificial Intelligence (AI)-based methods for performing medical diagnosis of diseases and conditions. An automated natural language processing (NLP) system performs deep learning techniques to extract clinically relevant information from electronic health records (EHRs). This framework provides a high diagnostic accuracy that demonstrates a successful AI-based method for systematic disease diagnosis and management.

Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Abstract: Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of diseases and conditions using artificial intelligence or machine learning approaches. Deep learning algorithms enable the automated analysis of medical images such as X-rays to generate predictions of comparable accuracy to clinical experts for various diseases and conditions including those afflicting the lung such as pneumonia.

Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having esophagus cancer, pancreatic cancer, or stomach cancer. Also provided herein are methods and kits for generating the methylation profile of a biomarker associated with esophagus cancer, pancreatic cancer, or stomach cancer.

Abstract: Disclosed herein are methods, probes, and kits for diagnosing the presence of cancer and/or a cancer type in a subject.

Abstract: Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.

Abstract: Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of ophthalmic diseases and conditions. Deep learning algorithms enable the automated analysis of ophthalmic images to generate predictions of comparable accuracy to clinical experts.

Abstract: Disclosed herein are methods and kits for identifying a subject as having esophagus cancer, pancreatic cancer, or stomach cancer. Also provided herein are methods and kits for generating the methylation profile of a biomarker associated with esophagus cancer, pancreatic cancer, or stomach cancer.

Abstract: Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having breast cancer. Also provided herein are methods and kits for determining the prognosis of a subject having breast cancer and for determining the progression of breast cancer in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having lung cancer. Also provided herein are methods and kits for determining the prognosis of a subject having lung cancer and for determining the progression of lung cancer in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having liver cancer. Also provided herein are methods and kits for determining the prognosis of a subject having liver cancer and for determining the progression of liver cancer in a subject.

Abstract: Disclosed herein are methods and kits for identifying a subject as having colon cancer. Also provided herein are methods and kits for determining the prognosis of a subject having colon cancer and for determining the progression of colon cancer in a subject.

Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).